189 related articles for article (PubMed ID: 37372960)
1. Lysophosphatidic Acid Receptor Signaling in the Human Breast Cancer Tumor Microenvironment Elicits Receptor-Dependent Effects on Tumor Progression.
Benesch MGK; Wu R; Tang X; Brindley DN; Ishikawa T; Takabe K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372960
[TBL] [Abstract][Full Text] [Related]
2. The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology.
Wasniewski T; Woclawek-Potocka I; Boruszewska D; Kowalczyk-Zieba I; Sinderewicz E; Grycmacher K
Oncol Rep; 2015 Nov; 34(5):2760-7. PubMed ID: 26327335
[TBL] [Abstract][Full Text] [Related]
3. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
4. Altered lysophosphatidic acid (LPA) receptor expression during hepatic regeneration in a mouse model of partial hepatectomy.
Simo KA; Niemeyer DJ; Hanna EM; Swet JH; Thompson KJ; Sindram D; Iannitti DA; Eheim AL; Sokolov E; Zuckerman V; McKillop IH
HPB (Oxford); 2014 Jun; 16(6):534-42. PubMed ID: 24750398
[TBL] [Abstract][Full Text] [Related]
5. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
Yu X; Zhang Y; Chen H
BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
[TBL] [Abstract][Full Text] [Related]
7. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
[TBL] [Abstract][Full Text] [Related]
8. LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells.
Doutt SW; Longo JF; Carroll SL
Glia; 2023 Mar; 71(3):742-757. PubMed ID: 36416236
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Matas-Rico E; Frijlink E; van der Haar Àvila I; Menegakis A; van Zon M; Morris AJ; Koster J; Salgado-Polo F; de Kivit S; Lança T; Mazzocca A; Johnson Z; Haanen J; Schumacher TN; Perrakis A; Verbrugge I; van den Berg JH; Borst J; Moolenaar WH
Cell Rep; 2021 Nov; 37(7):110013. PubMed ID: 34788605
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
Sokolov E; Eheim AL; Ahrens WA; Walling TL; Swet JH; McMillan MT; Simo KA; Thompson KJ; Sindram D; McKillop IH
J Surg Res; 2013 Mar; 180(1):104-13. PubMed ID: 23182454
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid.
Fernandes MF; Tomczewski MV; Duncan RE
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456981
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Functional Evidence Supports LPAR1 as a Susceptibility Gene for Hypertension.
Xu K; Ma L; Li Y; Wang F; Zheng GY; Sun Z; Jiang F; Chen Y; Liu H; Dang A; Chen X; Chun J; Tian XL
Hypertension; 2015 Sep; 66(3):641-6. PubMed ID: 26123684
[TBL] [Abstract][Full Text] [Related]
13. Study of lysophosphatidic acid receptors (LPARs) in buffalo uterus demonstrated upregulation of LPAR1 and LPAR6 in early pregnancy.
Sadam A; Parida S; Padol AR; Verma AD; Baba NA; Khuman WM; Srivastava V; Panigrahi M; Singh TU; Sarkar SN
Theriogenology; 2017 Sep; 99():90-97. PubMed ID: 28708504
[TBL] [Abstract][Full Text] [Related]
14. LPAR2 and LPAR4 are the Main Receptors Responsible for LPA Actions in Ovarian Endometriotic Cysts.
Kowalczyk-Zieba I; Woclawek-Potocka I; Wasniewski T; Boruszewska D; Grycmacher K; Sinderewicz E; Staszkiewicz J; Wolczynski S
Reprod Sci; 2019 Jan; 26(1):139-150. PubMed ID: 29621954
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer.
Tao K; Guo S; Chen R; Yang C; Jian L; Yu H; Liu S
Mol Diagn Ther; 2019 Feb; 23(1):127-138. PubMed ID: 30694446
[TBL] [Abstract][Full Text] [Related]
16. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
Quan M; Cui JJ; Feng X; Huang Q
Tumour Biol; 2017 Mar; 39(3):1010428317694544. PubMed ID: 28347252
[TBL] [Abstract][Full Text] [Related]
17. The Role of Lysophosphatidic Acid Receptors in Ovarian Cancer: A Minireview.
Cui R; Bai H; Cao G; Zhang Z
Crit Rev Eukaryot Gene Expr; 2020; 30(3):265-272. PubMed ID: 32749113
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid receptor 6 regulated by miR-27a-3p attenuates tumor proliferation in breast cancer.
Lei J; Guo S; Li K; Tian J; Zong B; Ai T; Peng Y; Zhang Y; Liu S
Clin Transl Oncol; 2022 Mar; 24(3):503-516. PubMed ID: 34510318
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin production in the human breast cancer tumor microenvironment mitigates tumor progression in early breast cancers.
Benesch MG; Wu R; Tang X; Brindley DN; Ishikawa T; Takabe K
Am J Cancer Res; 2023; 13(7):2790-2813. PubMed ID: 37559999
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin-lysophosphatidic acid receptor 5 axis evokes endothelial dysfunction via reactive oxygen species signaling.
Janovicz A; Majer A; Kosztelnik M; Geiszt M; Chun J; Ishii S; Tigyi GJ; Benyó Z; Ruisanchez É
Exp Biol Med (Maywood); 2023 Oct; 248(20):1887-1894. PubMed ID: 37837357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
